James Lawrence
Rheumatology · Mobile, ALNPI 1669657896
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 31.0% of the total. That places this record below the midpoint for rheumatology clinicians in AL, where the typical reported total is $8,965.
Across 372 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- GSK$914
- Pfizer$823
- Boehringer Ingelheim$703
- AstraZeneca$554
- plus $3K from 24 others
What the payments were for
- Food & beverage$9,75397%
- Education$3233%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 120 | $3,122 |
| Johnson & Johnson(2 entities) | 48 | $1,168 |
| GSK | 35 | $914 |
| Pfizer | 24 | $823 |
| Boehringer Ingelheim | 22 | $703 |
| AstraZeneca | 15 | $554 |
| Amgen | 14 | $544 |
| Aurinia Pharma U.S., Inc. | 21 | $432 |
| ANI Pharmaceuticals, Inc. | 20 | $401 |
| UCB, Inc. | 21 | $377 |
| Lilly USA, LLC | 3 | $156 |
| Regeneron Healthcare Solutions, Inc. | 2 | $150 |
| Mallinckrodt Hospital Products Inc. | 4 | $140 |
| Sanofi | 3 | $119 |
| Forte Bio-pharma LLC | 1 | $60 |
| E.r. Squibb & Sons, L.L.C. | 1 | $49 |
| Strongbridge US Inc. | 3 | $46 |
| Janssen Scientific Affairs, LLC | 1 | $44 |
| Cumberland Pharmaceuticals, Inc. | 2 | $40 |
| Scilex Pharmaceuticals Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Bristol Myers Squibb | 1 | $22 |
| Gilead | 1 | $22 |
| Sandoz | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Exact Sciences | 1 | $15 |
| Sobi, Inc | 1 | $15 |
| Novartis | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,075 in reported general payments places this provider in the 50th percentile of 90 rheumatology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 204 | $1,526,337 |
| RinvoqUpadacitinib | 110 | $754,592 |
| BenlystaBelimumab | 78 | $412,600 |
| XeljanzTofacitinib Citrate | 70 | $412,260 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $390,569 |
| OfevNintedanib Esylate | 19 | $259,030 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $197,222 |
| LupkynisVoclosporin | 13 | $189,711 |
| Enbrel SureclickEtanercept | 21 | $150,764 |
| ProlateOxycodone Hcl/Acetaminophen | 39 | $73,772 |
| OtezlaApremilast | 12 | $66,130 |
| Dupixent PenDupilumab | 15 | $58,328 |
| OzempicSemaglutide | 48 | $57,880 |
| XifaxanRifaximin | 14 | $44,030 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 275 | $38,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $3,122 | $769,214124 claims |
| PfizerXeljanz, Eliquis | $823 | $422,52187 claims |
| GSKBenlysta | $914 | $412,60078 claims |
| Boehringer IngelheimOfev | $703 | $259,03019 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $432 | $189,71113 claims |
| AmgenOtezla, Prolia | $544 | $85,62123 claims |
| Forte Bio-pharma LLCProlate | $60 | $73,77239 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $40 | $1,02920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Mobile
- Gino DivittorioMobile$139K
- Thomas McGeeMobile$12K
- Teresa OglesbyMobile$11K
- Yanming XingMobile$11K
- Sonia SavaniMobile$10K
- Thomas MyersMobile$9K
- Hamdy AhmedMobile$5K
- Daren ScroggieMobile$4K
- Anthony TurkiewiczMountain Brk$2.2M
- Jeffrey CurtisBirmingham$612K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.